Citation Tools
Poster Presentations
Psoriatic arthritis
THU0440 Ixekizumab Provides Sustained Improvement up To 52 Weeks of Disease Activity as Assessed by Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug (bDMARD)-Naive Patients with Active Psoriatic Arthritis
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- THU0440 Ixekizumab Provides Sustained Improvement up To 52 Weeks of Disease Activity as Assessed by Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug (bDMARD)-Naive Patients with Active Psoriatic Arthritis